Ascelia Completes FDA Meeting on Orviglance

5 sourcesUpdated Sep 10, 2026

Ascelia Pharma completed a planned Type A meeting with the U.S. Food and Drug Administration on September 9, 2026, to discuss issues raised in the agency’s Complete Response Letter for Orviglance’s marketing application. The company is awaiting the FDA’s official meeting minutes, expected within about 30 days, before outlining the drug’s regulatory path forward.

Sponsored

In this story:

Sponsored

More on this story

Back to News

Health

Recalled Broccoli Sprouts Linked to 22-Case Salmonella Outbreak

A multistate outbreak of Salmonella Bovismorbificans linked to broccoli sprouts from Evergreen Fresh Sprouts LLC has sickened 22 people across Washington, Montana, Idaho and Utah, with two hospitalizations and illnesses occurring between July 7 and August 26. The FDA and CDC urge recalls of Evergreen Fresh Sprouts broccoli sprouts with expiration dates of Sept 7, 9, 11, 14, and 16, and traceback investigations point to Evergreen Fresh Sprouts in Moyie Springs, Idaho, as the common grower, with this outbreak separate from the Everything Sprouts alfalfa-sprouts cases.

9 sources

Health

Food recalls expand nationwide; California warned

Last updatedSep 10, 2026

Does this breakdown look right?

Sponsored

How it spread

Broke ainvest.com · Sep 8, 6:01 AM ETCenter +6h5 sources +44h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

Coverage

Sponsored

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Sponsored

The August–2026 period has seen a sharp rise in food recalls across the U.S. and Canada, driven by a string of salmonella, cyclospora, and other contamination concerns that have prompted widespread product withdrawals and warnings. Experts and surveys suggest recalls may be increasing in frequency and scale, fueling consumer anxiety about the safety of the food supply, even as some data remain inconclusive about total yearly totals.

6 sources

Sponsored

Business

Telix completes BiPASS trial enrollment, aligns with FDA on NDA path

Telix has completed enrollment of 350 patients in its Phase 3 BiPASS trial evaluating Ga-68 PSMA-PET plus MRI for pre-biopsy prostate cancer detection, with the aim of improving diagnostic accuracy and reducing unnecessary biopsies. The company also aligned with the FDA on a New Drug Application pathway that could support reimbursement and broaden patient access if approved, a development that sparked investor interest.

9 sources